196170.KQ Alteogen Inc.
KOEHealthcareAs of 2026-08-09 03:19
Why 196170.KQ matters now
Alteogen Inc. (196170.KQ) is a Korea stock in Healthcare. The latest InvestLog snapshot shows ₩305,000.00 with +3.92% on the session and ₩16.34T in market capitalization.
Valuation context is available even where detailed statement rows are sparse: InvestLog currently shows P/E 125.51, gross margin 82.8%, and operating margin 41.8%.
Valuation
P/E (TTM)
125.51
PEG
—
P/B
32.28
P/S
104.13
EV/EBITDA
203.97
DCF Value
—
FCF Yield
0.5%
Div Yield
0.1%
Margins & Returns
Gross Margin
82.8%
Operating Margin
41.8%
Net Margin
63.7%
ROE
31.2%
ROA
17.8%
ROIC
10.0%
Listing Info
Market
Korea
Exchange
KOE
Currency
KRW
Sector
Healthcare
Industry
Biotechnology
Country
KR
ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars. The company develops ALT-P1, a long-acting human growth hormone that is in the Phase IIa clinical trial; and ALT-Q2, a long-acting active form of coagulation factor VII for the treatment of hemophilia based on its NexP technology. It is also involved in the development of ALT-P7, a targeted breast/gastric cancer drug that is in the Phase I clinical trial; ALT-Q5, an antibody-drug conjugate (ADC) for the treatment of ovarian cancer based on its NexMab ADC technology; and ALT-LS2, a SC (subcutaneous) formulation of trastuzuamb for the treatment of breast and gastric cancer. The company has a strategic alliance with Kissei Pharmaceutical for the development of ALT-L9, a biosimilar of Eylea (Aflibercept) which is currently under Phase 1 trial; Cristalia for the development of ALT-L2, a biosimilar of Herceptin (Trastuzumab), a monoclonal antibody for the treatment of breast cancer, which is in the Phase II clinical trial; and Biogen Inc. to develop subcutaneous (SC) formulations of biologics utilizing ALT-B4. ALTEOGEN Inc. was founded in 2008 and is headquartered in Daejeon, South Korea.